ReviewRegenerative therapy2026
Genetically engineered hypoimmunogenic iPSCs: Strategies and considerations for clinical applications.
Review in Regenerative therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Induced pluripotent stem cell (iPSC)-based therapies are rapidly advancing toward clinical implementation, with increasing numbers of trials and approvals for allogeneic iPSC-derived cell products. However, immune rejection remains a major barrier to the broad application of "off-the-shelf" allogeneic cell therapies for various diseases and injuries. With current advances in genetic engineering technologies, including genome editing, it is possible to establish a low-immunogenic cell product by disrupting immune recognition molecules and by overexpressing immunosuppressive factors. This review provides a comprehensive overview of current genetic engineering strategies for generating hypoimmunogenic iPS cells. Because multiplex genome editing and transgene integration may raise safety concerns, we further outline quality-control considerations for clinical-grade hypoimmunogenic iPSC products, including assessment of on-target outcomes, off-target mutations, structural variants, chromosomal abnormalities, residual editing components, and vector-related risks. Finally, we review current clinical development of genetically engineered hypoimmunogenic iPSC-derived products and discuss future challenges, including the importance of safety profiling and international regulatory harmonization. Understanding the advantages and limitations of each engineering and validation strategy will be critical for translating hypoimmunogenic iPSCs into safe, effective, and globally accessible regenerative therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.